scispace - formally typeset
G

Graeme Irvine Stevenson

Researcher at Merck & Co.

Publications -  34
Citations -  1925

Graeme Irvine Stevenson is an academic researcher from Merck & Co.. The author has contributed to research in topics: Indole test & Glycine. The author has an hindex of 24, co-authored 34 publications receiving 1887 citations. Previous affiliations of Graeme Irvine Stevenson include Merck Sharp & Dohme Federal Credit Union.

Papers
More filters
Journal ArticleDOI

L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity.

TL;DR: The identification of L-685,458 is reported as a structurally novel inhibitor of AβPP γ-secretase activity, with a similar potency for Alzheimer's disease targeting the N- and C-termini of the Aβ peptide.
Journal ArticleDOI

4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor.

TL;DR: Molecular modeling studies show that the 4-carbonyl groups of the kynurenic acids, the tetrahydroquinolines, and related antagonists based on N-(chlorophenyl)glycine, can interact with a single putative H-bond donor on the receptor.
Journal ArticleDOI

Novel 5-HT3 antagonists. Indole oxadiazoles.

TL;DR: Results have been incorporated into a proposed binding model for the 5-HT3 antagonist binding site, in which the optimum distance between the aromatic binding site and the basic amine is 8.4-8.9 A and the steric limitations are defined by van der Waals difference mapping.
Journal ArticleDOI

Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists.

TL;DR: It is shown that binding of the compounds to plasma protein limits their brain penetration, and it is suggested that it is necessary to either keep log P low or pKa high to obtain good central nervous system activity.
Journal ArticleDOI

3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically active anticonvulsants acting by antagonism at the glycine site of the N-methyl-D-aspartate receptor complex.

TL;DR: Novel antagonists at the glycine site of the NMDA receptor have been designed in which the anionic functionality is a vinylogous acid, in the form of a 4-hydroxyquinolin-2(1H)-one, which was tested for their ability to prevent audiogenic seizure in DBA/2 mice.